U.S. markets closed

Synlogic, Inc. (SYBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3800+0.3800 (+12.67%)
At close: 4:00PM EDT

3.4200 +0.04 (1.18%)
After hours: 7:58PM EDT

Sign in to post a message.
  • B
    Bruno
    I'm not sure what I am reading. Fidelity investment has suddenly taken a 15.459% position in Synlogic, Inc.?
    Form SC 13G SYNLOGIC, INC. Filed by: FMR LLC
    1:12 PM ET, 05/10/2021 - US Securities and Exchange Commission
    http://archive.fast-edgar.com/20210510/A5LFK222C222DJZ2222G2ZZXLMAIZ222F232
    Filed on: May 10, 2021
  • B
    Bruno
    Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth
    https://www.nasdaq.com/articles/companies-like-synlogic-nasdaq%3Asybx-are-in-a-position-to-invest-in-growth-2021-05-10
    May 10, 2021

    Does Synlogic Have A Long Cash Runway?

    A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Synlogic last reported its balance sheet in December 2020, it had zero debt and cash worth US$100m. In the last year, its cash burn was US$40m. So it had a cash runway of about 2.5 years from December 2020. That's decent, giving the company a couple years to develop its business.
  • B
    Bruno
    Synlogic, Inc. (SYBX)
    Three reasons why I love you:
    1. No Debt
    2. $100M Cash
    3. Price Target $11
  • Y
    Yahoo Finance Insights
    Synlogic is up 14.67% to 3.44
  • B
    Bruno
    To go from no holding to 15%, is earth shaking, to say the least.
  • B
    Blue
    Synlogic presents data from SYNB1891 Phase 1 trial at AACR Annual Meeting

    Synlogic presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research annual meeting. SYNB1891 is an investigational drug being evaluated in an ongoing Phase 1 clinical trial for the treatment of solid tumors and lymphoma. SYNB1891 is composed of an engineered Synthetic Biotic strain of E. coli Nissle that produces cyclic di-AMP, a stimulator of the STING pathway. This mechanism can play a critical role in the initiation of an anti-tumor immune response via activation of APCs and presentation of tumor antigens. Findings from the monotherapy cohorts include: SYNB1891 is safe and well-tolerated as an intratumoral injection in a heterogenous population; No dose limiting toxicities or SYNB1891-related infections; Dose levels through 1e7 live cells demonstrate target engagement as assessed by dose-dependent increases in serum cytokines, upregulation of ISGs and presence of tumor infiltrating lymphocytes; Evidence of durable stable disease was seen in 2 patients and was associated with upregulation genes tied to immune activation and increased intratumoral lymphocytes. These data support continued dose escalation in the monotherapy and combination arms. The combination arm of the study combines escalating dose levels of SYNB1891 with a fixed dose of a PD-L1 checkpoint inhibitor antibody to establish a recommended Phase 2 dose for the combination regimen. Data from both arms will continue to be reported over the course of 2021, with mature combination therapy data expected by the end of the year.

    4/11/2021
  • B
    Bruno
    Analysts Are Bullish on These Healthcare Stocks: Synlogic (SYBX), UnitedHealth (UNH)

    4/16/2021

    There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Synlogic (SYBX) and UnitedHealth (UNH) with bullish sentiments.

    Synlogic (SYBX)

    Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Synlogic today and set a price target of $10.00. The company’s shares closed Thursday at $3.16.

    According to TipRanks, Amusa is a 5-star analyst with an average return of 31.4% and a 50.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Adverum Biotechnologies, and Taysha Gene Therapies.

    The word on The Street in general, suggests a Strong Buy analyst consensus rating for Synlogic with a $15.00 average price target.
  • B
    Bruno
    JonesTrading analyst Lina Kaminski initiated coverage of Synlogic with a Buy rating and $15 price target. Kaminski sees "a unique buying opportunity" ahead of the release of proof of concept data readouts of SYNB1618 for phenylketonuria and SYNB8802 for enteric hyperoxaluria in mid-2021. Both data releases could potentially represent "major inflection points" for shares from current levels, Kaminski added.

    3/18/2021
  • E
    Eric M W
    --Analyst Actions: Jones Trading Starts Synlogic at Buy With $15 Price Target
    8:29 AM ET, 03/18/2021 - MT Newswires
    08:29 AM EDT, 03/18/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

    Price: 4.5500, Change: +0.37, Percent Change: +8.85
  • f
    fpdtls@
    Excellent news @ the conference, yet still light volume. I believe this will move upward fast once the news of the great work they're doing spreads.
    Bullish
  • J
    Jason
    now we know why the downward price pressure. stock offering.
  • f
    fpdtls@
    SYBX .. bring on the luck of the IRISH!
  • G
    GND
    What's happening?
  • C
    C. Craig
    This stock had a 95-97 rating on InvestorsObserver a week/ 10 days ago with heavy promotion as 'strong buy.' I bought the stock at $5.02. The next day the rating was 87, now it's 70. The stock has lost FORTY PERCENT of its value in a week! It's selling at $3.10 now. The selling was with large relative trades. Does anyone know where we can find out if there is INSIDER SELLING? They are due to report earnings or rather losses in a week. If there has been a lot of insider trading, it's time to get a lawyer and the SEC involved.
  • f
    fpdtls@
    Buying the dip and holding
    Bullish
  • C
    C. Craig
    Something must be bad with the earning coming out in two days if the stock is tumbling yesterday and today. Not good.
  • J
    Jason
    i can't decide whether the MMs are just cleaning out the weak habds and this is going to close higher, or the results were uninspiring and the price action reflects this fact. your guess is as good as mine!
  • f
    fpdtls@
    they are going to do big things!
    Bullish
  • J
    Jason
    looks like the after hours crowd isn't impressed with the PR. oh well.